$1.04
0.97%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US0070251097
Symbol
ADTX

Aditx Therapeutics Inc Stock price

$1.04
+0.05 5.32% 1M
-12.39 92.25% 6M
-46.41 97.81% YTD
-6,419.96 99.98% 1Y
-2,819,998.96 100.00% 3Y
-53,399,998.96 100.00% 5Y
-101,199,998.96 100.00% 10Y
-101,199,998.96 100.00% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.01 0.97%
ISIN
US0070251097
Symbol
ADTX
Industry

Key metrics

Basic
Market capitalization
$5.2m
Enterprise Value
$9.5m
Net debt
$4.4m
Cash
$320.0k
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | 0.0
P/S
517.6 | 0.2
EV/Sales
952.6 | 0.4
EV/FCF
negative
P/B
0.4
Financial Health
Equity Ratio
27.6%
Return on Equity
-455.0%
ROCE
-182.6%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$10.0k | $21.3m
EBITDA
$-21.7m | -
EBIT
$-22.1m | $-9.2m
Net Income
$-31.0m | $-804.4m
Free Cash Flow
$-22.6m
Growth (TTM | estimate)
Revenue
-97.0% | 16,255.4%
EBITDA
34.6% | -
EBIT
34.4% | 66.9%
Net Income
28.3% | -1,893.6%
Free Cash Flow
-15.4%
Margin (TTM | estimate)
Gross
-4,365.3%
EBITDA
-179,008.3% | -
EBIT
-182,748.8%
Net
-256,539.7% | -3,783.3%
Free Cash Flow
-186,854.6%
More
EPS
$-14.8
FCF per Share
$-7.1
Short interest
2.5%
Employees
26
Rev per Employee
$10.0k
Show more

Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.01 0.01
97% 97%
100%
- Direct Costs 0.54 0.54
13% 13%
5,400%
-0.53 -0.53
253% 253%
-5,300%
- Selling and Administrative Expenses 18 18
0% 0%
184,200%
- Research and Development Expense 3.16 3.16
79% 79%
31,600%
-22 -22
35% 35%
-216,600%
- Depreciation and Amortization 0.45 0.45
21% 21%
4,500%
EBIT (Operating Income) EBIT -22 -22
34% 34%
-221,126%
Net Profit -31 -31
28% 28%
-310,400%

In millions USD.

Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aditx Therapeutics Inc Stock News

Neutral
Business Wire
9 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc. (“Adimune”), which is pioneering a DNA-based therapeutic platform designed to reprogram the immune system. Adimune's intellectual property portfolio now inc...
Neutral
PRNewsWire
13 days ago
-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives -- -- Ensures a broader range of contraceptive choices is available to women state-wide -- SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- On August 15, 2025, Illinois enacted House Bill 3489, a measure designed to broaden access to contraception for its residents. This legislation permits...
Neutral
PRNewsWire
15 days ago
-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug P...
More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office United States
CEO Amro Albanna
Employees 26
Founded 2017
Website aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today